NACDS' opinion piece cites a Drug Channels Institute analysis that DIR fees “have grown faster than most people realize” and reached a record $9.1 billion in 2019.
Expansive comments to CMS demonstrate that success of healthcare transformation relies on removing barriers to pharmacy care
The U.S. Supreme Court will review the Eighth Circuit Court’s decision that put the brakes on Arkansas’ PBM law that would ensure that pharmacy reimbursement rates cover pharmacies’ costs of purchasing drugs.
Pharmacists strong again in latest Gallup “honesty and ethics” survey
Substance use disorder (SUD) treatment could benefit from pharmacists’ accessibility and expertise, NACDS wrote in detailed letters to 15 Medicaid program directors.
The refreshed microsite at AccessAgenda.NACDS.org supports NACDS' advocacy campaigns on priority topics.
In comments to CMS, NACDS says weakening of state access standards is flawed policymaking, and threatens to harm patient health and increase Medicaid costs
Pharmacy welcomes letter from over 80 percent of Committee members to Trump Administration, urging closure of Medicare regulatory loophole as legislative push continues
Industry collaboration; advancing opioid abuse prevention; and fighting phantom “DIR” fees stood among key themes at Sunday Business Program.
The total number of NACDS RxIMPACT 2019 in-district events to promote DIR relief priorities now stands at 72—and counting.
